Tender Details | ||||||||
|
||||||||
Deadline * | ||||||||
|
||||||||
Client Address | ||||||||
|
||||||||
More Information | ||||||||
Know More |
Similar Tenders
- Ref No: 8259327
- Location: Germany
Conclusion Of Non Exclusive Discount Agreements According To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Hydrocortisone Cre 2 5 Mg N1
- Deadline: 10 May 2026
- Ref No: 8260726
- Location: Germany
Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Hydrocortisone Tab 10 Mg
- Deadline: 10 May 2026
- Ref No: 5301821
- Location: Bulgaria
Delivery Of Medicinal Products Which Are Included In Appendix 2 Of The Pds For The Needs Of Umbal Kanev Ad
- Deadline: 27 May 2027
- Ref No: 5332318
- Location: Germany
Dynamic Procurement System Dbs For Green Electricity Deliveries From 2025 For The City Of Wolfsburg
- Deadline: 23 Apr 2026
- Ref No: 5396790
- Location: Germany
Conclusion Of A Non Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For Medicinal Products Containing The Active Ingredient L
- Deadline: 27 Apr 2026
- Ref No: 6688119
- Location: Germany
Dynamic Procurement System For Electricity Supplies From 2025 For The City Of Paderborn
- Deadline: 26 Jun 2025
- Ref No: 4641976
- Location: Germany
Medicines With The Active Ingredient Combination Oxycodone And Naloxone Atc N02Aa55
- Deadline: 28 Feb 2026
- Ref No: 3133479
- Location: Israel
Requests For Financial Participation Of The Ministry Of Energy In Conferences Seminars And Exhibitions
- Deadline: 31 Dec 2029
- Ref No: 4638957
- Location: Germany
Medicines With The Active Ingredient Tacrolimus Atc L04Ad02
- Deadline: 28 Feb 2026
- Ref No: 5226107
- Location: Germany
Medicines With The Active Ingredient Combination Vilanterol Umeclidinium Bromide And Fluticasone Furoate Atc R03Al08
- Deadline: 31 Mar 2026
- Ref No: 5976401
- Location: Germany
Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Baclofen In The Dosage Form Inf
- Deadline: 10 May 2026